TrialAntimicrobial agents and chemotherapy2010

Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli.

Eduardo L López et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.